Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | THPO | P40225 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27671779 | 0.81 | F2 (0.35) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15549079 | 0.73 | MEN1 (0.36) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL2915827 | 0.73 | — | — | |
| SCHEMBL11466101 | 0.71 | PLA2G7 (0.46) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL3333138 | 0.70 | PIK3CD (0.40) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15550136 | 0.70 | KDM4E (0.41) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL15549868 | 0.70 | PIK3CD (0.36) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL10622890 | 0.70 | TSHR (0.39) | KMT2AMEN1LMNACYP3A4CYP2C9 | |
| SCHEMBL9344572 | 0.69 | KMT2A (0.42) | KMT2AMEN1LMNACYP2C9PIK3CD | |
| SCHEMBL668723 | 0.68 | HDAC6 (0.33) | HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2010-06-10 | — | — | US | disclosed |
| EP-0140327-B1 | BIS-DIOXOPIPERAZINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, ANTITUMOR AGENTS COMPRISING THEM AND COMPOSITIONS CONTAINING THEM | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1990-05-23 | — | — | EP | disclosed |
| US-4650799-A | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-03-17 | — | — | US | disclosed |
| EP-0140327-A2 | Bis-dioxopiperazine derivatives, process for their preparation, antitumor agents comprising them and compositions containing them | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144704-A1 | Method of reducing amyloid-beta peptide levels using a bisdioxopiperazine | IAPP, APP, BACE1 | KMT2A 4542/4885MEN1 1316/4885LMNA 2044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.